{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:52:51Z","timestamp":1776372771863,"version":"3.51.2"},"reference-count":24,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,3,28]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>A man in his 70s with a history of unresectable hepatocellular carcinoma (HCC) treated with nivolumab presented with a blistering rash 14 months after nivolumab initiation. Biopsies and direct immunofluorescence confirmed the diagnosis of bullous pemphigoid (BP). BP is an autoimmune skin disorder in which autoantibodies bind to the dermal\u2013epidermal junction. It is a rare sequela of programmed cell death protein-1 (PD-1) inhibitors that can develop after treatment initiation and typically resolve soon after discontinuation. Most cases are reported in melanoma and non-small cell lung cancers, and rarely in HCC irrespective of the timing of onset. We describe a rare presentation of remote BP with PD-1 inhibitor use in HCC. PD-1 inhibitor-induced BP is a rare cutaneous immune-related adverse event, and this case highlights the variability in onset and chronicity.<\/jats:p>","DOI":"10.1136\/bcr-2024-263285","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:30:51Z","timestamp":1744129851000},"page":"e263285","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Remote presentation of nivolumab-induced bullous pemphigoid in hepatocellular carcinoma"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-0848","authenticated-orcid":false,"given":"Ashley","family":"Yoo","sequence":"first","affiliation":[{"name":"Internal Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Chen","sequence":"additional","affiliation":[{"name":"Internal Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Sarma","sequence":"additional","affiliation":[{"name":"The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherinne","family":"Arundel","sequence":"additional","affiliation":[{"name":"Internal Medicine, DC VA Medical Center, Washington, District of Columbia, USA"},{"name":"Internal Medicine, George Washington University Hospital, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025082712525955000_18.4.e263285.1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12366"},{"key":"2025082712525955000_18.4.e263285.2","unstructured":"Rendon A , Rayi A . Nivolumab. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567801\/"},{"key":"2025082712525955000_18.4.e263285.3","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108"},{"key":"2025082712525955000_18.4.e263285.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"2025082712525955000_18.4.e263285.5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic Immune-Related Adverse Events Following Adjuvant Anti\u2013PD-1 Therapy for High-risk Resected Melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025082712525955000_18.4.e263285.6","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"2025082712525955000_18.4.e263285.7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025082712525955000_18.4.e263285.8","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3457","article-title":"A Systematic Review of Drug-Induced Pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025082712525955000_18.4.e263285.9","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2025082712525955000_18.4.e263285.10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.15679","article-title":"Review of autoimmune blistering diseases: the Pemphigoid diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082712525955000_18.4.e263285.11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025082712525955000_18.4.e263285.12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/dermatopathology9010010","article-title":"Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation","volume":"9","author":"Niebel","year":"2022","journal-title":"Dermatopathology (Basel)"},{"key":"2025082712525955000_18.4.e263285.13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025082712525955000_18.4.e263285.14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025082712525955000_18.4.e263285.15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor-induced bullous pemphigoid","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025082712525955000_18.4.e263285.16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025082712525955000_18.4.e263285.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025082712525955000_18.4.e263285.18","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.12788\/cutis.0011","article-title":"Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer","volume":"105","author":"Schwartzman","year":"2020","journal-title":"Cutis"},{"key":"2025082712525955000_18.4.e263285.19","article-title":"Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab","volume":"15","author":"Olsen","year":"2023","journal-title":"Cureus"},{"key":"2025082712525955000_18.4.e263285.20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025082712525955000_18.4.e263285.21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","article-title":"A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","journal-title":"j immunotherapy cancer"},{"key":"2025082712525955000_18.4.e263285.22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"key":"2025082712525955000_18.4.e263285.23","article-title":"A Case of Bullous Pemphigoid Associated With Nivolumab Therapy","volume":"14","author":"Gotera","year":"2022","journal-title":"Cureus"},{"key":"2025082712525955000_18.4.e263285.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215451","article-title":"A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors","volume":"14","author":"Shalata","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:53:10Z","timestamp":1756324390000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bcr-2024-263285"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263285","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}